Latest news with #ICL
The Star
27-05-2025
- Health
- The Star
JKR preparing cost estimate for Sarawak Cancer Centre, says Deputy Premier
Deputy Premier Datuk Dr Sim Kui Hian delivering his winding-up speech at the Sarawak Legislative Assembly on Tuesday (May 27). KUCHING: The Public Works Department (JKR) is preparing the cost estimation for the Sarawak Cancer Centre project, says Datuk Seri Dr Sim Kui Hian. The Sarawak Deputy Premier said the estimated cost would be based on a 310-bed facility. "The Sarawak Cancer Centre project is currently at the pre-implementation stage." JKR Malaysia is appointed as the implementing agency," he said during his winding-up speech in the Sarawak Legislative Assembly on Tuesday (May 27). The cancer centre will be developed by the Federal Government in collaboration with the Sarawak government, as announced by Prime Minister Datuk Seri Anwar Ibrahim during Budget 2025. He thanked the Sarawak government for providing initial financing, estimated at RM1bil, which will be reimbursed by Putrajaya. Dr Sim also said the federal Health Ministry allocated RM48.8mil for upgrading, renovation, and repair works of health clinics in Sarawak this year. Of the total, RM40mil was allocated under the Bitara Madani initiative for upgrading dilapidated clinics and RM7.5mil for rural clinic services. Another RM1.3mil was allocated for upgrading and repairing health workers' quarters. Additionally, Dr Sim said the Health Ministry approved RM14.5mil each for invasive cardiac laboratories (ICL) at Miri and Sibu hospitals to expand cardiology services. "Apart from that, RM12.5mil was approved to replace the existing ICL at the Sarawak Heart Centre," he said.
Yahoo
22-05-2025
- Business
- Yahoo
STAAR Surgical Announces Participation in Upcoming Investor Conferences
LAKE FOREST, Calif., May 22, 2025--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2025 Virtual Ophthalmology ForumDate: Tuesday, May 27, 2025Format: Meetings and Webcast Fireside ChatWebcast: 2:00 PM ET, Webcast Link Wells Fargo 2025 West Coast Bus TourDate: Thursday, May 29, 2025Location: Laguna Beach, CAFormat: Fireside Chat; No Webcast William Blair 45th Annual Growth Stock ConferenceDate: Wednesday, June 4, 2025Location: Chicago, ILFormat: Meetings and Webcast Slide PresentationWebcast: 9:40 AM ET, Webcast Link Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Location: New York, NYFormat: Meetings Only Investor meeting participation is by invitation only from each sponsoring brokerage firm. The live and archived webcast for each event, where applicable, will also be available on STAAR's investor website at About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL's are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections at Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at View source version on Contacts Investors & Media Brian MooreVice President, Investor Relations and Corporate Development(626) 303-7902, Ext. 3023bmoore@ Investors - Asia Niko Liu, CFADirector, Investor Relations and Corporate Development - Asia+852-6092-5076nliu@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
STAAR Surgical Announces Participation in Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Wells Fargo 2025 West Coast Bus Tou r Date: Thursday, May 29, 2025 Location: Laguna Beach, CA Format: Fireside Chat; No Webcast William Blair 45th Annual Growth Stock Conference Date: Wednesday, June 4, 2025 Location: Chicago, IL Format: Meetings and Webcast Slide Presentation Webcast: 9:40 AM ET, Webcast Link Jefferies Global Healthcare Conference Date: Thursday, June 5, 2025 Location: New York, NY Format: Meetings Only Investor meeting participation is by invitation only from each sponsoring brokerage firm. The live and archived webcast for each event, where applicable, will also be available on STAAR's investor website at About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL's are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections at Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at
Yahoo
19-05-2025
- Business
- Yahoo
ICL Group: Q1 Earnings Snapshot
TEL AVIV, Israel (AP) — TEL AVIV, Israel (AP) — ICL Group Ltd (ICL) on Monday reported profit of $91 million in its first quarter. The Tel Aviv, Israel-based company said it had profit of 7 cents per share. Earnings, adjusted for non-recurring costs, came to 9 cents per share. The potash and fertilizer producer posted revenue of $1.77 billion in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ICL at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
19-05-2025
- Business
- San Francisco Chronicle
ICL Group: Q1 Earnings Snapshot
TEL AVIV, Israel (AP) — TEL AVIV, Israel (AP) — ICL Group Ltd (ICL) on Monday reported profit of $91 million in its first quarter. The Tel Aviv, Israel-based company said it had profit of 7 cents per share. Earnings, adjusted for non-recurring costs, came to 9 cents per share. The potash and fertilizer producer posted revenue of $1.77 billion in the period. _____
